BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36586085)

  • 1. Impact of early postoperative factors on changes in skeletal muscle mass after esophagectomy in older patients with esophageal cancer.
    Harada T; Tatematsu N; Ueno J; Koishihara Y; Konishi N; Fukushima T; Fujiwara H; Fujita T; Hijikata N; Wada A; Ishikawa A; Tsuji T
    Eur Geriatr Med; 2023 Feb; 14(1):203-210. PubMed ID: 36586085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal Muscle Loss After Esophagectomy Is an Independent Risk Factor for Patients with Esophageal Cancer.
    Nakashima Y; Saeki H; Hu Q; Tsuda Y; Zaitsu Y; Hisamatsu Y; Ando K; Kimura Y; Oki E; Mori M
    Ann Surg Oncol; 2020 Feb; 27(2):492-498. PubMed ID: 31549319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Impact of the Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy on Older Patients with Esophageal Cancer.
    Harada T; Tsuji T; Ueno J; Koishihara Y; Konishi N; Hijikata N; Ishikawa A; Kotani D; Kojima T; Fujiwara H; Fujita T
    Ann Surg Oncol; 2022 Dec; 29(13):8131-8139. PubMed ID: 35978207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Impact of Postoperative Loss of Skeletal Muscle Mass in Patients Aged 70 Years or Older with Esophageal Cancer.
    Harada T; Tatematsu N; Ueno J; Koishihara Y; Konishi N; Hijikata N; Ishikawa A; Tsuji T; Fujiwara H; Fujita T
    Ann Surg Oncol; 2022 Sep; 29(9):5638-5645. PubMed ID: 35499789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of Skeletal Muscle Loss During Early Postoperative Period in Elderly Patients with Esophageal Cancer.
    Takahashi K; Watanabe M; Kozuki R; Toihata T; Okamura A; Imamura Y; Mine S; Ishizuka N
    Ann Surg Oncol; 2019 Oct; 26(11):3727-3735. PubMed ID: 31313039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of skeletal muscle measurement by computed tomography in patients with esophageal cancer: changes in skeletal muscle mass due to neoadjuvant therapy and the effect on the prognosis.
    Yamamoto M; Ozawa S; Koyanagi K; Kazuno A; Ninomiya Y; Yatabe K; Higuchi T; Kanamori K; Tajima K
    Surg Today; 2023 Jun; 53(6):692-701. PubMed ID: 36763134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal muscle loss in the postoperative acute phase after esophageal cancer surgery as a new prognostic factor.
    Maeda N; Shirakawa Y; Tanabe S; Sakurama K; Noma K; Fujiwara T
    World J Surg Oncol; 2020 Jun; 18(1):143. PubMed ID: 32591002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.
    Kamitani N; Migita K; Matsumoto S; Wakatsuki K; Kunishige T; Nakade H; Miyao S; Sho M
    Surg Today; 2019 Dec; 49(12):1022-1028. PubMed ID: 31309328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Optimal Definition of Sarcopenia for Predicting Postoperative Pneumonia after Esophagectomy in Patients with Esophageal Cancer.
    Nambara M; Miki Y; Tamura T; Yoshii M; Toyokawa T; Tanaka H; Lee S; Muguruma K; Shibata T; Ohira M
    World J Surg; 2021 Oct; 45(10):3108-3118. PubMed ID: 34189621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
    Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
    World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer.
    Mayanagi S; Tsubosa Y; Omae K; Niihara M; Uchida T; Tsushima T; Yokota T; Sato H; Naito T; Yasui H
    Ann Surg Oncol; 2017 Nov; 24(12):3741-3747. PubMed ID: 28861809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of reduced skeletal muscle volume on clinical outcome after esophagectomy for esophageal cancer: A retrospective study.
    Nagata K; Tsujimoto H; Nagata H; Harada M; Ito N; Kanematsu K; Nomura S; Horiguchi H; Hiraki S; Hase K; Yamamoto J; Ueno H
    Medicine (Baltimore); 2018 Jul; 97(30):e11450. PubMed ID: 30045268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Preoperative Skeletal Muscle Mass and Nutritional Status on Short-and Long-Term Outcomes After Esophagectomy for Esophageal Cancer: A Retrospective Observational Study : Impact of Psoas Muscle Mass and Body Mass on Esophagectomy.
    Shichinohe T; Uemura S; Hirano S; Hosokawa M
    Ann Surg Oncol; 2019 May; 26(5):1301-1310. PubMed ID: 30725311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of skeletal muscle wasting during neoadjuvant chemotherapy on postoperative anastomotic leakage in patients with esophageal cancer.
    Fujihata S; Ogawa R; Nakaya S; Hayakawa S; Okubo T; Sagawa H; Tanaka T; Takahashi H; Matsuo Y; Takiguchi S
    Esophagus; 2021 Apr; 18(2):258-266. PubMed ID: 32889673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer.
    Kita R; Miyata H; Sugimura K; Tanaka K; Makino T; Yamashita K; Yamasaki M; Motoori M; Shiraishi O; Kimura Y; Yasuda T; Yano M; Doki Y
    Clin Nutr; 2021 Jun; 40(6):4380-4385. PubMed ID: 33526287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are muscle parameters obtained by computed tomography associated with outcome after esophagectomy for cancer?
    Kemper M; Molwitz I; Krause L; Reeh M; Burdelski C; Kluge S; Yamamura J; Izbicki JR; de Heer G
    Clin Nutr; 2021 Jun; 40(6):3729-3740. PubMed ID: 34130018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Handgrip Strength Predicts Postoperative Pneumonia After Thoracoscopic-Laparoscopic Esophagectomy for Patients with Esophageal Cancer.
    Kurita D; Oguma J; Ishiyama K; Hirano Y; Kanamori J; Daiko H
    Ann Surg Oncol; 2020 Sep; 27(9):3173-3181. PubMed ID: 32500345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
    Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
    Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
    Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
    Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer.
    den Boer RB; Jones KI; Ash S; van Boxel GI; Gillies RS; O'Donnell T; Ruurda JP; Sgromo B; Silva MA; Maynard ND
    BJS Open; 2020 Oct; 4(5):847-854. PubMed ID: 32841538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.